Together for Short Lives
Call the Helpline 0808 8088 100

Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain

Journal title
The Clinical journal of pain
Publication year
2011
Author(s)
Kanbayashi, Y.; Hosokawa, T.; Okamoto, K.; Fujimoto, S.; Konishi, H.; Otsuji, E.; Yoshikawa, T.; Takagi, T.; Miki, T.; Taniwaki, M.
Pages
664-7
Volume
27
Number
8

OBJECTIVES: To identify predictive factors requiring high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone to transdermal fentanyl in patients with cancer pain. METHODS: The participants were 76 hospitalized terminal cancer patients who underwent opioid switching from oxycodone or morphine sustained-release tablet to transdermal fentanyl at our hospital between January 2009 and June 2010. The conversion dose was calculated as transdermal fentanyl (25 mug/h)/oral morphine (60 mg) or oxycodone (40 mg)=1. The response evaluated was the dose conversion ratio [transdermal fentanyl/oral morphine or oxycodone (conversion dose to fentanyl)]=Y and was taken to be 0 for Y

Research abstracts